Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Mezagitamab in Adults With Primary IgA Nephropathy
2025-520825-19-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Mezagitamab arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in proteinuria at Week 36. Planned start Sep 2025; status: authorised.
02
Drugs
mezagitamab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2025-520825-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520825-19-00.